AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Current Value
$6.741 Year Return
Current Value
$6.741 Year Return
Market Cap
$273.06M
P/E Ratio
-1.11
1Y Stock Return
-0.59%
1Y Revenue Growth
-12.85%
Dividend Yield
0.00%
Price to Book
1.4
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TXG | 49.21% | $1.64B | -68.30% | 0.00% |
ABCL | 49.14% | $800.44M | -37.56% | 0.00% |
GRAL | 46.32% | $459.22M | -13.00% | 0.00% |
TWI | 43.64% | $424.30M | -48.58% | 0.00% |
NVST | 42.26% | $3.49B | -15.41% | 0.00% |
ALLO | 41.77% | $444.50M | -24.82% | 0.00% |
AGL | 41.58% | $655.11M | -85.55% | 0.00% |
PGEN | 40.95% | $228.91M | -28.00% | 0.00% |
PAYS | 40.19% | $176.71M | +37.50% | 0.00% |
CRBU | 40.13% | $180.20M | -62.45% | 0.00% |
SHYF | 38.97% | $460.16M | +20.72% | 1.50% |
CYRX | 38.37% | $342.80M | -48.82% | 0.00% |
JACK | 37.76% | $880.37M | -33.18% | 3.82% |
EYE | 37.70% | $888.30M | -42.18% | 0.00% |
FATE | 37.24% | $248.29M | -11.02% | 0.00% |
AMWL | 37.02% | $121.95M | -67.11% | 0.00% |
SIBN | 36.88% | $516.68M | -29.40% | 0.00% |
PLOW | 36.77% | $572.50M | -7.57% | 4.79% |
CLFD | 36.70% | $398.66M | +4.48% | 0.00% |
HCAT | 36.65% | $458.79M | 0.00% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PULM | -0.01% | $19.83M | +202.98% | 0.00% |
XBIO | -0.07% | $6.01M | +21.36% | 0.00% |
PENG | -0.14% | $911.79M | +4.97% | 0.00% |
AON | 0.20% | $82.00B | +16.33% | 0.70% |
CCEC | 0.22% | $1.02B | +28.03% | 3.26% |
RLI | 0.24% | $8.01B | +29.25% | 0.64% |
NERV | 0.25% | $14.69M | -58.00% | 0.00% |
WHF | 0.30% | - | - | 14.53% |
EDR | 0.32% | $9.01B | +19.26% | 0.82% |
TMUS | -0.35% | $270.63B | +56.92% | 0.83% |
AGX | -0.35% | $2.01B | +224.91% | 0.85% |
NFLX | 0.36% | $372.45B | +83.46% | 0.00% |
UTHR | -0.38% | $16.10B | +56.54% | 0.00% |
GLP | 0.38% | $1.77B | +51.33% | 5.50% |
QNRX | 0.44% | $3.20M | -85.07% | 0.00% |
CMTL | 0.45% | $84.44M | -76.16% | 0.00% |
NEUE | -0.46% | $40.93M | -34.13% | 0.00% |
AFL | 0.51% | $61.74B | +35.69% | 1.35% |
SCKT | -0.54% | $10.88M | +15.32% | 0.00% |
CNA | 0.55% | $13.16B | +23.03% | 3.61% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PGR | -17.03% | $149.10B | +57.29% | 0.45% |
LPLA | -13.33% | $23.55B | +38.13% | 0.38% |
MCK | -13.10% | $78.15B | +35.51% | 0.42% |
VIST | -10.55% | $4.75B | +67.10% | 0.00% |
PRPO | -8.24% | $9.10M | -13.65% | 0.00% |
ACGL | -7.96% | $36.00B | +16.84% | 0.00% |
IBKR | -7.16% | $20.20B | +131.83% | 0.37% |
RNR | -7.04% | $13.74B | +23.09% | 0.58% |
ALL | -6.61% | $52.06B | +45.67% | 1.85% |
EG | -6.59% | $15.92B | -8.98% | 2.02% |
SNY | -6.48% | $120.34B | +3.11% | 4.25% |
STG | -6.41% | $35.67M | +7.92% | 0.00% |
BTCT | -6.38% | $42.61M | +353.33% | 0.00% |
VIRT | -6.33% | $3.17B | +110.38% | 2.60% |
HUSA | -6.13% | $16.69M | -11.56% | 0.00% |
RJF | -5.96% | $33.06B | +55.96% | 1.11% |
DHT | -5.82% | $1.72B | +5.04% | 9.18% |
OXBR | -5.72% | $19.05M | +178.18% | 0.00% |
HIHO | -5.68% | $8.63M | 0.00% | 6.12% |
LFWD | -5.61% | $16.21M | -63.99% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XHE | 48.22% | $213.41M | 0.35% |
ARKG | 44.15% | $1.13B | 0.75% |
IWC | 43.92% | $933.99M | 0.6% |
EDOC | 43.60% | $40.86M | 0.68% |
IWN | 43.14% | $13.17B | 0.24% |
PRFZ | 43.06% | $2.65B | 0.39% |
FYX | 43.00% | $959.00M | 0.6% |
GSSC | 42.89% | $529.86M | 0.2% |
VTWO | 42.87% | $12.38B | 0.1% |
XRT | 42.83% | $451.85M | 0.35% |
IWM | 42.76% | $75.73B | 0.19% |
SPSM | 42.74% | $12.72B | 0.03% |
CALF | 42.51% | $8.93B | 0.59% |
VIOV | 42.51% | $1.44B | 0.15% |
RSPH | 42.48% | $885.96M | 0.4% |
VIOO | 42.41% | $3.12B | 0.1% |
IJR | 42.22% | $90.05B | 0.06% |
SMDV | 42.02% | $754.57M | 0.4% |
IJS | 41.91% | $7.37B | 0.18% |
VBK | 41.87% | $19.31B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CANE | 0.32% | $17.72M | 0.29% |
PREF | -0.49% | $999.92M | 0.55% |
TPMN | 0.75% | $40.60M | 0.65% |
TBIL | -0.77% | $4.38B | 0.15% |
FLTR | -0.84% | $1.79B | 0.14% |
BILZ | 0.88% | $563.02M | 0.14% |
XHLF | 1.13% | $874.27M | 0.03% |
SGOV | -1.26% | $27.53B | 0.09% |
DBMF | -1.35% | $1.02B | 0.85% |
DBE | -1.42% | $50.13M | 0.77% |
FLRN | -1.50% | $2.33B | 0.15% |
USCI | 1.71% | $185.47M | 1.07% |
JUCY | -1.74% | $324.29M | 0.6% |
XBIL | 1.75% | $637.70M | 0.15% |
COMT | 1.78% | $829.06M | 0.48% |
JBBB | 1.82% | $1.26B | 0.49% |
TAIL | -2.03% | $67.98M | 0.59% |
CORN | 2.18% | $61.12M | 0.2% |
FTSM | 2.23% | $6.08B | 0.45% |
CLOI | 2.30% | $715.40M | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -27.29% | $388.04M | 1.43% |
USDU | -17.49% | $201.97M | 0.5% |
UUP | -13.46% | $309.25M | 0.77% |
VIXY | -13.07% | $195.31M | 0.85% |
CTA | -12.81% | $350.27M | 0.78% |
HIGH | -10.65% | $302.78M | 0.51% |
KCCA | -10.55% | $220.51M | 0.87% |
DBO | -9.99% | $217.57M | 0.77% |
EQLS | -9.76% | $76.08M | 1% |
IBTE | -9.66% | $1.70B | 0.07% |
DBA | -9.61% | $755.88M | 0.93% |
AGZD | -9.11% | $142.76M | 0.23% |
KMLM | -8.19% | $353.87M | 0.9% |
FMF | -4.53% | $244.61M | 0.95% |
MINT | -4.17% | $11.62B | 0.35% |
BOXX | -4.01% | $4.43B | 0.1949% |
UNG | -4.01% | $908.80M | 1.06% |
ULST | -3.89% | $535.47M | 0.2% |
WEAT | -3.54% | $120.27M | 0.28% |
BSCO | -2.48% | $2.35B | 0.1% |
Yahoo
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.
Yahoo
Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.
Yahoo
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Yahoo
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
Yahoo
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.